Phio Pharmaceuticals, Inc. (NASDAQ: PHIO) is a clinical‐stage biotechnology company focused on the discovery and development of dual RNA interference (RNAi) therapeutics. Utilizing its proprietary Transitional RNAi (TRiMTM) platform, Phio aims to simultaneously silence multiple gene targets to achieve enhanced therapeutic activity. The company’s core mission is to advance next‐generation RNAi compounds with potential applications in oncology and immuno‐oncology.
Phio’s TRiMTM platform is designed around the delivery of synthetic, double‐stranded RNA duplexes that can be engineered to target specific combinations of genes implicated in tumor growth and immune evasion. The lead programs in its pipeline include PH‐762, being evaluated in collaboration with Janssen for solid tumor indications, and PH‐687, an internally developed candidate with potential in immuno‐oncology. Both candidates are currently in preclinical or early clinical testing, as the company seeks to validate safety, tolerability and proof-of‐mechanism in human studies.
In addition to its collaboration with Janssen, Phio has established partnerships with academic institutions and research organizations to explore the broader utility of TRiMTM in hard‐to‐treat cancers. The company’s R&D efforts are supported by preclinical data demonstrating potent gene knockdown and immune modulation, laying the groundwork for combination strategies with established immunotherapies.
Founded in 2014 and headquartered in Newtown, Pennsylvania, Phio Pharmaceuticals operates primarily in the United States while engaging with global research networks. The company is led by President and Chief Executive Officer Seth Hewitt, whose background in translational oncology and RNAi drug development guides Phio’s strategic direction and clinical advancement efforts.
AI Generated. May Contain Errors.
Free PHIO Stock Alerts